flatexDEGIRO Offers Crypto Trading via Partnership With BISON (Boerse Stuttgart Group)
19.5.2022 10:39:00 EEST | Business Wire | Press release
flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR), Europe's largest and fastest growing retail online broker and Boerse Stuttgart Group, Europe's sixth largest exchange group, today announced the signing of a Memorandum of Understanding (MoU) on a partnership in crypto trading. This will give flatexDEGIRO customers direct access to trading in major cryptocurrencies via convenient and direct in-app access from flatex and DEGIRO with an accelerated onboarding process. For this purpose, Boerse Stuttgart Group provides its integrated offer in the crypto business, with uncomplicated trading via the retail platform BISON and use the secure crypto custody service operated by the custodian blocknox. The aim is to launch first at flatex Germany and Austria by the end of the third quarter of 2022, followed by the expansion of the offer to all DEGIRO customers.
Frank Niehage, CEO of flatexDEGIRO: "As the European market leader in online stock trading, cryptocurrencies add a key element to our already very broad product range. Together with the Robo-Advisory offering planned for summer 2022 via our partner Whitebox, flatexDEGIRO will offer its customers the most comprehensive product range of all European online brokers. For us, taking this step with such a renowned and trustworthy partner as Boerse Stuttgart Group was an indispensable requirement for the sustainable protection of our customers, especially in such a young and volatile asset class as cryptocurrencies."
"As the leading European exchange group in the crypto sector, we are pleased to have gained the leading European online broker flatexDEGIRO as a partner. The partnership is part of our strategy to continue to grow as a regulated and integrated provider of crypto services, in both the retail and institutional markets," said Dr Matthias Voelkel, CEO of Boerse Stuttgart Group.
Muhamad Chahrour, CFO of flatexDEGIRO and CEO of DEGIRO: "flatexDEGIRO enables more than 300 million Europeans to take control of their financial future with easy and secure access to the capital market - without restrictions or lazy compromises. Thanks to our technical edge, we offer our customers the broadest product range in the industry on one of the most convenient and stable platforms – at the lowest prices, especially in the most important European growth markets."
"Our partnership with flatexDEGIRO creates enormous added value for customers: They benefit from easy processes, attractive transaction costs and custody of cryptocurrencies free of charge. We can jointly unlock new investor groups and serve their growing interest in digital assets," explains Dr Ulli Spankowski, Chief Digital Officer of Boerse Stuttgart Group and Head of BISON.
Customers can trade the cryptocurrencies Bitcoin, Ethereum, Litecoin, Ripple, Bitcoin Cash, Chainlink and Uniswap on BISON free of charge – 24 hours a day, seven days a week. The admission of further cryptocurrencies will follow in the next months. Only the spread between the displayed buying and selling prices is charged. There are no additional costs for customers, for example for deposits or withdrawals of cryptocurrencies. blocknox GmbH, a subsidiary of Boerse Stuttgart Group, takes care of the custody of cryptocurrencies on an escrow basis. For this purpose, blocknox GmbH has implemented a multi-level security concept.
For further information please contact:
Press contact flatexDEGIRO:
Achim Schreck Phone +49 (0) 69 450001 0
Head of IR & Corporate Communications achim.schreck@flatexdegiro.com
Press Contact Boerse Stuttgart Group:
Johannes Frevert Phone + 49 711 222 985-711
Media Spokesperson johannes.frevert@boerse-stuttgart.de
About flatexDEGIRO AG
flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR) operates a leading and fastest growing online brokerage platform in Europe. Based on modern, in-house state-of-the-art technology, customers of the flatex and DEGIRO brands are offered a wide range of independent products with execution on top TIER 1 exchanges. The technological edge as well as the high efficiency and strong economies of scale enable flatexDEGIRO to continuously improve its service offering to customers, including commission-free brokerage.
With more than 2 million customer accounts and over 91 million securities transactions processed in 2021, flatexDEGIRO is the largest retail online broker in Europe. In times of bank consolidation, low interest rates and digitalisation, flatexDEGIRO is ideally positioned for further growth. Within the next five years, flatexDEGIRO aims to expand its customer base to 7- 8 million customer accounts and process 250-350 million transactions per year - even in years of low volatility.
Further information at https://www.flatexdegiro.com/de
About Boerse Stuttgart Group
Boerse Stuttgart Group is the sixth largest exchange group in Europe with strategic pillars in the capital markets business and in the digital and crypto business. It operates exchanges in Germany, Sweden and Switzerland. As a true pioneer, it has built the largest digital and crypto business of all the European exchange groups. Boerse Stuttgart has a workforce of 650 and premises in Stuttgart, Berlin, Stockholm, Zurich and Ljubljana.
Further information at https://www.boerse-stuttgart.de
| Language: | English |
| Company: | flatexDEGIRO AG |
| Rotfeder-Ring 7 | |
| 60327 Frankfurt / Main | |
| Germany | |
| Phone: | +49 (0) 69 450001 0 |
| E-mail: | ir@flatexdegiro.com |
| Internet: | www.flatexdegiro.com |
| ISIN: | DE000FTG1111 |
| WKN: | FTG111 |
| Indices: | SDAX |
| Listed: | Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: |
1356185 |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220519005505/en/
Contact information
Name: Achim Schreck
Tel: +49 (0) 69 450001 1700
Email: achim.schreck@flatexdegiro.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom